Literature DB >> 18313627

Heart failure with preserved ejection fraction: hypertension, diabetes, obesity/sleep apnea, and hypertrophic and infiltrative cardiomyopathy.

Akshay Desai1, James C Fang.   

Abstract

The detailed pathophysiology of heart failure with preserved ejection fraction (HF-PEF) remains an area of active research and controversy; however, abnormalities of diastolic function are generally believed to play an important role. Most commonly, diastolic dysfunction occurs as a consequence of myocyte hypertrophy, endomyocardial fibrosis, and abnormalities of intracellular calcium handling that are related to normal myocardial aging and accelerated by comorbidities such as hypertension, diabetes, coronary artery disease, and obesity. In this article, three fundamental risk factors are considered for "secondary" diastolic dysfunction and HF-hypertension, diabetes, and obesity-with an emphasis on the clinical epidemiology, pathophysiologic mechanisms, and treatment implications of each. The article concludes with a brief discussion of "primary" diastolic HF due to infiltrative or restrictive cardiomyopathies.

Entities:  

Mesh:

Year:  2008        PMID: 18313627     DOI: 10.1016/j.hfc.2007.11.001

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  15 in total

Review 1.  Type 2 diabetes, mitochondrial biology and the heart.

Authors:  Michael N Sack
Journal:  J Mol Cell Cardiol       Date:  2009-02-13       Impact factor: 5.000

Review 2.  Role of circulating factors in cardiac aging.

Authors:  Antonio Cannatà; Gabriella Marcon; Giovanni Cimmino; Luca Camparini; Giulio Ciucci; Gianfranco Sinagra; Francesco S Loffredo
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 3.  Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium.

Authors:  Francesco S Loffredo; Andriana P Nikolova; James R Pancoast; Richard T Lee
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

4.  Low glial angiotensinogen improves body habitus, diastolic function, and exercise tolerance in aging male rats.

Authors:  Leanne Groban; Hao Wang; Frederico S M Machado; Aaron J Trask; Stephen B Kritchevsky; Carlos M Ferrario; Debra I Diz
Journal:  Cardiovasc Endocrinol       Date:  2012-09-01

5.  Diastolic dysfunction evaluated by cardiac magnetic resonance: the value of the combined assessment of atrial and ventricular function.

Authors:  Giovanni Donato Aquaro; Fausto Pizzino; Anna Terrizzi; Scipione Carerj; Bijoy K Khandheria; Gianluca Di Bella
Journal:  Eur Radiol       Date:  2018-08-20       Impact factor: 5.315

Review 6.  Caloric excess or restriction mediated modulation of metabolic enzyme acetylation-proposed effects on cardiac growth and function.

Authors:  Michael N Sack
Journal:  Biochim Biophys Acta       Date:  2011-02-03

Review 7.  Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine.

Authors:  Vincenzo B Polsinelli; Sanjiv J Shah
Journal:  Expert Opin Pharmacother       Date:  2017-02-17       Impact factor: 3.889

Review 8.  Cardiac aging and heart disease in humans.

Authors:  Marja Steenman; Gilles Lande
Journal:  Biophys Rev       Date:  2017-03-20

Review 9.  Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.

Authors:  Erik H Howell; Scott J Cameron
Journal:  Cardiol J       Date:  2016-09-26       Impact factor: 2.737

10.  Treatment of heart failure with normal ejection fraction.

Authors:  Nazha Hamdani; Walter J Paulus
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.